Plicamycin
FDA-approved product (injectable, injection), marketed as Mithracin.
- Registered studies
- 3
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Other cytotoxic antibiotics
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA58.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli32.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis47.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
3registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Plicamycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Nintedanib EsylateExisting use: Idiopathic pulmonary fibrosis, Interstitial pneumonitis, Non-small cell lung carcinoma and 1 more48.5% AI-predicted activityagainst E. coli50+ registered studies
- TicagrelorExisting use: Acute coronary syndrome, Acute myocardial infarction, Coronary artery disease and 6 more48.5% AI-predicted activityagainst E. coli50+ registered studies
- RegadenosonExisting use: Cardiovascular disease, Myocardial Perfusion Imaging48.4% AI-predicted activityagainst E. coli50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more48.2% AI-predicted activityagainst E. coli50+ registered studies
- Lazertinib MesylateExisting use: Non-small cell lung carcinoma48.2% AI-predicted activityagainst E. coliNo documented evidence found
- SitagliptinExisting use: Diabetes mellitus, Hyperlipidemia, Myocardial infarction and 2 more48.2% AI-predicted activityagainst E. coli50+ registered studies
- ClozapineExisting use: Psychosis, Schizoaffective disorder, Schizophrenia48.1% AI-predicted activityagainst E. coli50+ registered studies
- FutibatinibExisting use: Cancer, Cholangiocarcinoma, Neoplasm48.0% AI-predicted activityagainst E. coli25 registered studies
- Atazanavir SulfateExisting use: HIV infection, HIV-1 infection, Infection and 1 more48.0% AI-predicted activityagainst E. coli50+ registered studies
- Daclatasvir DihydrochlorideExisting use: Chronic hepatitis C virus infection, Viral disease48.0% AI-predicted activityagainst E. coli2 registered studies
- AripiprazoleExisting use: Aggressive behavior, Agitation, Autism and 8 more48.0% AI-predicted activityagainst E. coli50+ registered studies
- Alclometasone DipropionateExisting use: Eye inflammation, Skin disease47.9% AI-predicted activityagainst E. coli2 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
NCT02859415 · start 2019-08-08
Registered record
- Registry ID
- NCT02859415
- Conditions
- Esophageal Neoplasms; Lung Neoplasms; Mesothelioma; Thymus Neoplasms; Neoplasms, Germ Cell and Embryonal
- Interventions
- Mithramycin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Terminated
- Start
- 2019-08-08
- Completion
- 2021-12-01
- Enrolment
- 3
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEsophageal Neoplasms; Lung Neoplasms; Mesothelioma; Thymus Neoplasms +1 moreInterventionMithramycinPhasePhase 1 / Phase 2Registry statusTerminatedMithramycin for Lung, Esophagus, and Other Chest Cancers
NCT01624090 · start 2012-09-06
Registered record
- Registry ID
- NCT01624090
- Conditions
- Lung Cancer; Esophageal Cancer; Mesothelioma; Gastrointestinal Neoplasms; Breast Cancer
- Interventions
- Mithramycin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2012-09-06
- Completion
- 2019-09-27
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLung Cancer; Esophageal Cancer; Mesothelioma; Gastrointestinal Neoplasms +1 moreInterventionMithramycinPhasePhase 2Registry statusTerminatedMithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma
NCT01610570 · start 2012-05-10
Registered record
- Registry ID
- NCT01610570
- Conditions
- Ewing Sarcoma; Sarcoma
- Interventions
- Mithramycin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Terminated
- Start
- 2012-05-10
- Completion
- 2014-05-21
- Enrolment
- 8
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEwing Sarcoma; SarcomaInterventionMithramycinPhasePhase 1 / Phase 2Registry statusTerminated